FDA Approves Unknown Drug — CIPLA

# FDA Approves CIPLA's Generic Drug Application Cipla Limited received FDA approval for its abbreviated new drug application (ANDA 213165) on February 2, 2026, positioning the company to capture market share in an established pharmaceutical segment. The approval strengthens Cipla's U.S. generic portfolio and is expected to enhance the company's competitive standing in a market characterized by increasing price competition and generic penetration.